Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
July 25, 2022 08:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 25, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 12, 2022 18:47 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 12, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Participate in LD Micro Invitational XII Conference
June 01, 2022 08:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., June 01, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET
|
Assertio Holdings, Inc.
Reaffirms Full Year Net Product Sales and Raises Full Year Non-GAAP Adjusted EBITDA Guidance Net Product Sales Up 37% and Non-GAAP Adjusted EBITDA Up 52% Compared to Prior Year Quarter Quarterly...
Assertio Holdings, Inc. to Report First Quarter 2022 Financial Results After the Close of Markets on Monday, May 9, 2022
April 22, 2022 09:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release first quarter 2022 financial results...
Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution
March 31, 2022 09:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 31, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT) and BlinkRx, the leading patient access solution, today announced a collaboration to support...
Assertio Reports Fourth Quarter and Full Year 2021 Financial Results
March 09, 2022 08:30 ET
|
Assertio Holdings, Inc.
$32.2 Million Fourth Quarter Net Product Sales, a 7% Increase from Fourth Quarter 2020 and $109.4 Million Full Year Net Product Sales $17.8 Million Fourth Quarter Non-GAAP Adjusted EBITDA, a 118%...
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results Before the Opening of Markets on Wednesday, March 9, 2022
March 02, 2022 09:05 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 02, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2021...
Assertio Holdings, Inc. to Participate in the H.C. Wainwright BioConnect Virtual Conference
January 10, 2022 09:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company’s Chief Executive Officer, Dan Peisert, and...
Assertio Holdings, Inc. Announces the Acquisition of Otrexup® (methotrexate) a Drug Device Combination from Antares Pharma, Inc.
December 15, 2021 17:35 ET
|
Assertio Holdings, Inc.
Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million Assertio will Pay Antares $18.0 Million Upfront and an Additional $26.0 Million in Deferred Payments Raises Full Year Net Product...